SAB BIOTHERAPEUTICS INC (SABS) Stock Price, Quote, News and Overview
NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock - Currency: USD
SABS Quote, Performance and Key Statistics
1.78
-0.03 (-1.66%)
The current stock price of SABS is 1.78 USD. In the past month the price decreased by -0.55%. In the past year, price decreased by -32.58%.
SABS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.08 | 328.06B | ||
| AMGN | AMGEN INC | 13.46 | 150.26B | ||
| GILD | GILEAD SCIENCES INC | 14.09 | 135.70B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.53B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.61 | 65.13B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.83B | ||
| ARGX | ARGENX SE - ADR | 98.77 | 35.40B | ||
| ONC | BEIGENE LTD-ADR | 6.1 | 25.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.69B | ||
| NTRA | NATERA INC | N/A | 21.46B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.04B | ||
| BIIB | BIOGEN INC | 8.12 | 18.81B |
Related stock screener links
About SABS
Company Profile
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Company Info
SAB BIOTHERAPEUTICS INC
777 W 41St St, Suite 401
Miami Beach FLORIDA US
CEO: Samuel J. Reich
Employees: 63
Phone: 13058452813
SAB BIOTHERAPEUTICS INC / SABS FAQ
What is the stock price of SAB BIOTHERAPEUTICS INC today?
The current stock price of SABS is 1.78 USD. The price decreased by -1.66% in the last trading session.
What is the ticker symbol for SAB BIOTHERAPEUTICS INC stock?
The exchange symbol of SAB BIOTHERAPEUTICS INC is SABS and it is listed on the Nasdaq exchange.
On which exchange is SABS stock listed?
SABS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SAB BIOTHERAPEUTICS INC stock?
10 analysts have analysed SABS and the average price target is 9.18 USD. This implies a price increase of 415.73% is expected in the next year compared to the current price of 1.78. Check the SAB BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SAB BIOTHERAPEUTICS INC worth?
SAB BIOTHERAPEUTICS INC (SABS) has a market capitalization of 16.54M USD. This makes SABS a Nano Cap stock.
How many employees does SAB BIOTHERAPEUTICS INC have?
SAB BIOTHERAPEUTICS INC (SABS) currently has 63 employees.
What are the support and resistance levels for SAB BIOTHERAPEUTICS INC (SABS) stock?
SAB BIOTHERAPEUTICS INC (SABS) has a support level at 1.78 and a resistance level at 1.86. Check the full technical report for a detailed analysis of SABS support and resistance levels.
Is SAB BIOTHERAPEUTICS INC (SABS) expected to grow?
The Revenue of SAB BIOTHERAPEUTICS INC (SABS) is expected to decline by -62.25% in the next year. Check the estimates tab for more information on the SABS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SAB BIOTHERAPEUTICS INC (SABS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SABS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SABS, evaluating the profitability, health, valuation and growth aspects
- SAB BIOTHERAPEUTICS INC (SABS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SAB BIOTHERAPEUTICS INC (SABS) Sales and EPS estimates to see what analysts future expectations are.
- SAB BIOTHERAPEUTICS INC (SABS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SAB BIOTHERAPEUTICS INC (SABS) Insider and Institutional Ownership to learn about the owners and their transactions.
- SAB BIOTHERAPEUTICS INC (SABS) Stock Chart to make your own analysis
- SAB BIOTHERAPEUTICS INC (SABS) Latest news and press-releases to stay up to date.
Does SAB BIOTHERAPEUTICS INC (SABS) stock pay dividends?
SABS does not pay a dividend.
When does SAB BIOTHERAPEUTICS INC (SABS) report earnings?
SAB BIOTHERAPEUTICS INC (SABS) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of SAB BIOTHERAPEUTICS INC (SABS)?
SAB BIOTHERAPEUTICS INC (SABS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.7).
What is the Short Interest ratio of SAB BIOTHERAPEUTICS INC (SABS) stock?
The outstanding short interest for SAB BIOTHERAPEUTICS INC (SABS) is 1.28% of its float. Check the ownership tab for more information on the SABS short interest.
SABS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SABS. When comparing the yearly performance of all stocks, SABS is a bad performer in the overall market: 77.95% of all stocks are doing better.
SABS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SABS. SABS may be in some trouble as it scores bad on both profitability and health.
SABS Financial Highlights
Over the last trailing twelve months SABS reported a non-GAAP Earnings per Share(EPS) of -3.7. The EPS increased by 42.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.92% | ||
| ROE | -160.11% | ||
| Debt/Equity | 0.15 |
SABS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to SABS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 19.46% and a revenue growth -62.25% for SABS